antipsychotics

BMS flag
Biotech

BMS' schizophrenia drug shows long-term benefit with new data

The crown jewel of BMS' $14 billion Karuna acquisition was schizophrenia drug KarXT, but five additional assets are awaiting further assessment.
Max Bayer Apr 6, 2024 1:15pm
one white and yellow capsule farther ahead than four other same-colored blue capsules

Karuna's new schizophrenia drug reaches FDA's desk

Sep 28, 2023 11:12am
A puzzle of the brain with one missing piece

Autoreceptor absence fuels dopamine dysfunction in schizophrenia

Nov 1, 2022 11:00am